300 Results

FDA approves Zirabev , bevacizumab biosimilar

 Added 24 days ago

The FDA has approved Pfizer’s bevacizumab biosimilar, bevacizumab-bvzr, referencing Avastin. The biosimilar will be sold as Zirabev. The drug has...

EU approves Talzenna for HER2- breast cancer

 Added 29 days ago

Pfizer Inc. announced that the European Commission approved Talzenna (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for...

FDA approves Kanjinti for breast cancer and gastric cancer

 Added 1 month ago

Amgen and Allergan plc announced that the FDA has approved Kanjinti (trastuzumab-anns) for all approved indications of the reference product,...

Overall survival results for Kisqali in combination with endocrine therapy in phase III MONALEESA-7 trial for (HR+/HER2-) advanced or metastatic breast cancer.

 Added 1 month ago

Novartis has announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy. The Phase III MONALEESA-7...

Eisai and MedSIR announce initiation of new study investigating HalavenĀ® (eribulin) treatment efficacy in metastatic breast cancer

 Added 1 month ago

REVERT study is a multicenter, randomised, phase II trial evaluating the efficacy of Halaven® (eribulin) monotherapy and eribulin plus endocrine therapy...

FDA gives premarket approval to Therascreen PIK3CA Kit as companion diagnostic for breast cancer.

 Added 1 month ago

Qiagen announced the immediate launch of its Therascreen PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory...

FDA approves Piqray + fulvestrant to treat hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer

 Added 1 month ago

Novartis announced the FDA has approved Piqray (alpelisib, formerly BYL 719) in combination with fulvestrant for the treatment of postmenopausal...

Additional data from SOPHIA study of margetuximab for HER2-positive metastatic breast cancer

 Added 2 months ago

MacroGenics, Inc.,has announced additional details of the results from the Phase III SOPHIA study of margetuximab in patients with HER2-positive...

Positive results from Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan to treat HER2-positive, unresectable breast cancer . Daiichi Sankyo + AstraZeneca

 Added 2 months ago

AstraZeneca and Daiichi Sankyo Company, Limited announced positive top-line results for the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan...

Global HER2 testing survey raises questions about priorities for breast cancer resources

 Added 2 months ago

A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries.

Load more